11870 related articles for article (PubMed ID: 11293263)
21. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
[TBL] [Abstract][Full Text] [Related]
22. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
23. Selectivity of the antimetastatic and cytotoxic effects of 1-p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt (+/-)-1,2-di(3,5-dioxopiperazin-1-yl)propane, and cyclophosphamide in mice bearing Lewis lung carcinoma.
Giraldi T; Sava G; Cuman R; Nisi C; Lassiani L
Cancer Res; 1981 Jun; 41(6):2524-8. PubMed ID: 7237446
[TBL] [Abstract][Full Text] [Related]
24. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
25. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
26. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
Milas L; Ito H; Hunter N
Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574
[TBL] [Abstract][Full Text] [Related]
27. Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs.
Rak J; Kuśnierczyk H; Strzadała L; Kłosiewicz S; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):389-97. PubMed ID: 2639635
[TBL] [Abstract][Full Text] [Related]
28. [The effect of cycloferon administration on the growth of transplantable tumors in rats and mice].
Zabezhinskiĭ MA; Popovich IG; Shtylik AV; Kovalenko AL; Anisimov VN
Vopr Onkol; 1998; 44(4):427-31. PubMed ID: 9807206
[TBL] [Abstract][Full Text] [Related]
29. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
30. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
31. Angiostatin potentiates cyclophosphamide treatment of metastatic disease.
Mauceri HJ; Seetharam S; Beckett MA; Schumm LP; Koons A; Gupta VK; Park JO; Manan A; Lee JY; Montag AG; Kufe DW; Weichselbaum RR
Cancer Chemother Pharmacol; 2002 Nov; 50(5):412-8. PubMed ID: 12439600
[TBL] [Abstract][Full Text] [Related]
32. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
33. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
34. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
35. Captopril augments antitumor activity of cyclophosphamide in mice.
Kowalski J; Herman ZS
Pol J Pharmacol; 1996; 48(3):281-5. PubMed ID: 9112663
[TBL] [Abstract][Full Text] [Related]
36. Protection by S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation- and cyclophosphamide-induced attenuation in antitumor resistance.
Milas L; McBride WH; Hunter N; Ito H
Cancer Res; 1984 Jun; 44(6):2382-6. PubMed ID: 6327014
[TBL] [Abstract][Full Text] [Related]
37. Effects of repeated exposure to cyclophosphamide on drug resistance and biological properties of a newly autonomy-acquired mouse mammary tumor (T4-OI320).
Takeda Y; Matsuzawa A; Kaneko T; Sekiguchi M; Fujii G
Jpn J Exp Med; 1988 Apr; 58(2):87-98. PubMed ID: 2842525
[TBL] [Abstract][Full Text] [Related]
38. Embryonal mass and hormone-associated effects of pregnancy inducing a differential growth of four murine tumors.
Bustuoabad OD; di Gianni PD; Franco M; Kordon EC; Vanzulli SI; Meiss RP; Grion LC; Díaz GS; Nosetto SH; Hockl P; Lombardi MG; Pasqualini CD; Ruggiero RA
Oncol Res; 2002; 13(3):147-60. PubMed ID: 12549624
[TBL] [Abstract][Full Text] [Related]
39. Combinations of mesna with cyclophosphamide or adriamycin in the treatment of mice with tumors.
Bernacki RJ; Bansal SK; Gurtoo HL
Cancer Res; 1987 Feb; 47(3):799-802. PubMed ID: 3100025
[TBL] [Abstract][Full Text] [Related]
40. Effects of combination estrogen:cyclophosphamide treatment on the growth of the MXT transplantable mammary tumor in the mouse.
Markaverich BM; Medina D; Clark JH
Cancer Res; 1983 Jul; 43(7):3208-11. PubMed ID: 6850631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
